• Profile
Close

Transplantation and diabetes (Transdiab): A pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation

BMC Nephrology May 05, 2019

Alnasrallah B, et al. - Researchers evaluated metformin for its feasibility, tolerability and effectiveness following renal transplantation in patients with impaired glucose tolerance in a single-center, unblinded, pilot randomized controlled trial (Transdiab). They randomized 19 participants to standard care or standard care and metformin 500 mg twice daily. Participants were then observed for 12 months. Both groups demonstrated comparable tolerability and effectiveness and no serious adverse events were seen. The secondary outcomes relating to the metabolic profile were also not different. According to the findings, metformin use after kidney transplantation appeared feasible and safe.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay